Exelixis - EXEL Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 12 month price objectives for Exelixis' shares. Their EXEL share price forecasts range from $21.00 to $42.00. On average, they predict the company's share price to reach $28.00 in the next year. This suggests a possible upside of 77.6% from the stock's current price.
View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts.

Exelixis' stock was trading at $18.28 at the beginning of 2022. Since then, EXEL stock has decreased by 13.7% and is now trading at $15.77.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our EXEL earnings forecast.

Exelixis, Inc. (NASDAQ:EXEL) issued its earnings results on Tuesday, November, 1st. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. The biotechnology company earned $411.74 million during the quarter, compared to the consensus estimate of $404.15 million. Exelixis had a trailing twelve-month return on equity of 13.11% and a net margin of 18.78%.

Exelixis issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.57 billion-$1.60 billion, compared to the consensus revenue estimate of $1.60 billion.

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.51%), Vanguard Group Inc. (9.70%), Renaissance Technologies LLC (4.97%), State Street Corp (4.04%), Farallon Capital Management LLC (3.31%) and Price T Rowe Associates Inc. MD (2.49%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends.

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXEL stock can currently be purchased for approximately $15.77.

Exelixis (NASDAQ:EXEL) has a market capitalization of $5.09 billion and generates $1.43 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.95 on an earnings per share basis.

The company employs 954 workers across the globe.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.